PLUR
$3.23
Pluri Inc., a biotechnology company, engages in the research, development, and manufacture of cell-based products, cell therapeutics, and related technologies for various industries.
Historical Price
Peer Comparison
Whystock Valuation Model
Fundamentals
Pluri Inc., a biotechnology company, engages in the research, development, and manufacture of cell-based products, cell therapeutics, and related technologies for various industries. It develops placenta-based cell therapy product candidates for the ...
Recent News
Pluri: Fiscal Q2 Earnings Snapshot
HAIFA, Israel (AP) — Pluri Inc. PLUR) on Thursday reported a loss of $6.5 million in its fiscal second quarter. The Haifa, Israel-based company said it had a loss of 71 cents per share.
Pluri showcases cell expansion platform as Resbiomed program advances
Pluri Inc CEO Yaky Yanay joined Steve Darling from Proactive to provide deeper insight into the company’s proprietary cell expansion technology and its strategic growth across both therapeutics and food technology. Yanay noted that Pluri has invested more than two decades in developing what he described as one of the most advanced and effective cell expansion systems globally, supported by an intellectual property portfolio of approximately 250 patents. Pluri currently operates across two core verticals. The first is focused on longevity, therapeutics, and aesthetics, where the company leverages placenta-derived cells to develop innovative biological solutions. The second vertical is centered on food technology, where Pluri’s scalable platform enables the production of cultivated meat, as well as key ingredients such as coffee, cocoa, and other agricultural inputs designed to address sustainability and supply chain challenges. Yanay also told Proactive that the company has successfully completed the first phase of its collaboration with Resbiomed Technologies OOD, a European biotechnology company specializing in extracellular-matrix (ECM)–based biomaterials and biologics for regenerative medicine. The program is being executed through Pluri’s contract development and manufacturing organization, PluriCDMO™. He explained that the initial phase of the collaboration focused on early-stage process development and feasibility assessments, all of which have now been completed. With these objectives achieved, the program is advancing into its next phase, representing a meaningful milestone in the partnership and setting the foundation for further development work. As part of the collaboration, Pluri is applying its proprietary placenta-based technologies and advanced bioprocessing expertise to assist Resbiomed in establishing robust protocols for tissue extraction, separation, and processing. These processes are designed to preserve, concentrate, and enhance endogenous collagen components, enabling the production of high-quality biological materials suitable for a broad range of regenerative medicine applications. The work builds on Pluri’s proven experience in placenta-derived manufacturing while complementing Resbiomed’s specialized focus on ECM-based biomaterials. Human collagen and collagen-rich materials are considered premium biological inputs due to strict sourcing, regulatory, and quality requirements. By combining Pluri’s scalable manufacturing capabilities with Resbiomed’s biomaterials expertise, the collaboration aims to help address these challenges and support the development of next-generation regenerative therapies. From Pluri’s perspective, the agreement highlights the growing demand for PluriCDMO™ services among companies developing advanced cell- and tissue-based technologies. Yanay emphasized that the collaboration further strengthens PluriCDMO’s position as a trusted partner for biologics and advanced biomaterials programs that require reproducibility, scalability, and rigorous manufacturing controls as they progress toward clinical and commercial development. #proactiveinvetors #nasdaq #tase #plur #yakyyanay #biotech #PluriCDMO #Resbiomed #RegenerativeMedicine #Biotechnology #ECMBiomaterials #Collagen #BiologicsManufacturing #CDMO #AdvancedTherapies #PlacentaBasedTech #TissueEngineering #LifeSciences #Bioprocessing #ProactiveInvestors
A US$3.4m Market Cap Boost Pleasing ToPluri Insiders
Pluri Inc. ( NASDAQ:PLUR ) insiders who purchased shares in the last 12 months were richly rewarded last week. The...
Pluri: Fiscal Q1 Earnings Snapshot
HAIFA, Israel (AP) — Pluri Inc. PLUR) on Wednesday reported a loss of $5.9 million in its fiscal first quarter. On a per-share basis, the Haifa, Israel-based company said it had a loss of 65 cents.
Pluri Subsidiary Coffeesai Partners with Mexico’s INCAFECH to Advance Cell-Based Coffee Manufacturing
Pluri Inc. (NASDAQ:PLUR) is one of the best long term penny stocks with huge upside potential. On October 8, Pluri announced that its wholly-owned subsidiary, Coffeesai Ltd., had signed a collaboration agreement with the Instituto del Café de Chiapas/INCAFECH, a public body of the State of Chiapas, Mexico. The purpose of this state-backed collaboration is […]